Equities analysts expect that Meridian Bioscience, Inc. (NASDAQ:VIVO) will post $53.35 million in sales for the current quarter, according to Zacks. Two analysts have provided estimates for Meridian Bioscience’s earnings. The highest sales estimate is $53.47 million and the lowest is $53.23 million. Meridian Bioscience reported sales of $54.13 million during the same quarter last year, which indicates a negative year-over-year growth rate of 1.4%. The firm is scheduled to issue its next earnings report on Thursday, April 26th.
On average, analysts expect that Meridian Bioscience will report full-year sales of $53.35 million for the current financial year, with estimates ranging from $208.59 million to $210.52 million. For the next fiscal year, analysts expect that the firm will report sales of $218.58 million per share, with estimates ranging from $216.75 million to $220.10 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Meridian Bioscience.
Meridian Bioscience (NASDAQ:VIVO) last posted its quarterly earnings data on Thursday, January 25th. The company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.01. The business had revenue of $52.30 million during the quarter, compared to analysts’ expectations of $49.00 million. Meridian Bioscience had a net margin of 10.46% and a return on equity of 17.00%. The business’s revenue was up 11.8% on a year-over-year basis. During the same period last year, the firm posted $0.15 earnings per share.
VIVO has been the subject of several recent analyst reports. Canaccord Genuity increased their price objective on shares of Meridian Bioscience from $14.00 to $16.00 and gave the company a “hold” rating in a report on Friday, January 26th. Zacks Investment Research lowered shares of Meridian Bioscience from a “buy” rating to a “hold” rating in a research note on Sunday, January 21st. Finally, BidaskClub lowered shares of Meridian Bioscience from a “hold” rating to a “sell” rating in a research note on Saturday, February 3rd.
A number of hedge funds have recently added to or reduced their stakes in VIVO. Advisor Group Inc. lifted its stake in Meridian Bioscience by 24.9% during the second quarter. Advisor Group Inc. now owns 7,720 shares of the company’s stock valued at $122,000 after purchasing an additional 1,537 shares during the last quarter. Jane Street Group LLC acquired a new stake in Meridian Bioscience during the fourth quarter valued at approximately $140,000. Verity Asset Management Inc. acquired a new stake in Meridian Bioscience during the fourth quarter valued at approximately $161,000. Hartford Investment Management Co. acquired a new stake in Meridian Bioscience during the third quarter valued at approximately $166,000. Finally, Nisa Investment Advisors LLC lifted its stake in Meridian Bioscience by 90.9% during the fourth quarter. Nisa Investment Advisors LLC now owns 13,020 shares of the company’s stock valued at $182,000 after purchasing an additional 6,200 shares during the last quarter. 89.12% of the stock is owned by institutional investors and hedge funds.
Meridian Bioscience (VIVO) traded down $0.05 during trading on Wednesday, hitting $14.50. 204,100 shares of the stock traded hands, compared to its average volume of 289,648. The company has a quick ratio of 3.96, a current ratio of 5.82 and a debt-to-equity ratio of 0.28. The company has a market capitalization of $613.46, a PE ratio of 21.32 and a beta of 0.98. Meridian Bioscience has a twelve month low of $12.45 and a twelve month high of $16.45.
The firm also recently announced a quarterly dividend, which was paid on Thursday, February 15th. Investors of record on Monday, February 5th were paid a dividend of $0.125 per share. This represents a $0.50 annualized dividend and a yield of 3.45%. The ex-dividend date of this dividend was Friday, February 2nd. Meridian Bioscience’s dividend payout ratio is presently 98.04%.
ILLEGAL ACTIVITY WARNING: This article was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another publication, it was illegally copied and republished in violation of international copyright and trademark law. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/02/19/meridian-bioscience-inc-vivo-expected-to-announce-quarterly-sales-of-53-35-million.html.
Meridian Bioscience Company Profile
Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.
Get a free copy of the Zacks research report on Meridian Bioscience (VIVO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.